Skip to content

Medicine Matters

Sharing successes, challenges and daily happenings in the Department of Medicine

Medicine Matters Home Article of the Week A quantitative approach for measuring the reservoir of latent HIV-1 proviruses

A quantitative approach for measuring the reservoir of latent HIV-1 proviruses

ARTICLE: A quantitative approach for measuring the reservoir of latent HIV-1 proviruses

AUTHORS: Katherine M. Bruner, Zheng WangFrancesco R. SimonettiAlexandra M. BenderKyungyoon J. KwonSrona SenguptaEmily J. FraySubul A. BegAnnukka A. R. AntarKatharine M. JenikeLynn N. BertagnolliAdam A. CapoferriJoshua T. KuferaAndrew Timmons, Christopher Nobles, John Gregg, Nikolas Wada, Ya-Chi Ho, Hao Zhang, Joseph B. Margolick, Joel N. Blankson, Steven G. Deeks, Frederic D. Bushman, Janet D. Siliciano, Gregory M. Laird & Robert F. Siliciano 

JOURNAL: Nature. 2019 Feb;566(7742):120-125. doi: 10.1038/s41586-019-0898-8. Epub 2019 Jan 30.

Abstract

A stable latent reservoir for HIV-1 in resting CD4+ T cells is the principal barrier to a cure1-3. Curative strategies that target the reservoir are being tested4,5 and require accurate, scalable reservoir assays. The reservoir was defined with quantitative viral outgrowth assays for cells that release infectious virus after one round of T cell activation1. However, these quantitative outgrowth assays and newer assays for cells that produce viral RNA after activation6 may underestimate the reservoir size because one round of activation does not induce all proviruses7. Many studies rely on simple assays based on polymerase chain reaction to detect proviral DNA regardless of transcriptional status, but the clinical relevance of these assays is unclear, as the vast majority of proviruses are defective7-9. Here we describe a more accurate method of measuring the HIV-1 reservoir that separately quantifies intact and defective proviruses. We show that the dynamics of cells that carry intact and defective proviruses are different in vitro and in vivo. These findings have implications for targeting the intact proviruses that are a barrier to curing HIV infection.

For a link to the full article, click here.

For a link to the abstract, click here.

nv-author-image

Kelsey Bennett